This aligns with recent reports of a novel immune/mesenchymal-enriched (IME) subtype in IDH-mutant astrocytoma, defined by gemistocytic differentiation, immune infiltration, and unfavorable prognosis [45]. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).